Arich Enterprise (4173) reported revenue of NT$183 million for Oct 2026, +68.1% year on year and +2.4% from the previous month. Revenue for Jan–Oct 2026 was NT$1.42 billion (+13.5% year on year).
Revenue for Oct 2026 was a record high (previous high: Sep 2026, NT$178.7 million). →
Year-on-year revenue growth: 4 months in a row. →
In Oct 2026, it ranked No. 46 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$183 million | +68.1% | +2.4% |
| Sep 2026 | NT$178.7 million | +42.1% | +23.9% |
| Aug 2026 | NT$144.2 million | +13.7% | +16.6% |
| Jul 2026 | NT$123.7 million | +7.3% | -14.0% |
| Jun 2026 | NT$143.8 million | -7.7% | +31.0% |
| May 2026 | NT$109.7 million | -6.4% | -10.6% |
| Apr 2026 | NT$122.7 million | +16.2% | -7.7% |
| Mar 2026 | NT$133 million | +25.6% | +31.1% |
| Feb 2026 | NT$101.4 million | -37.9% | -42.7% |
| Jan 2026 | NT$177 million | +42.0% | +15.9% |
| Dec 2025 | NT$152.7 million | +22.8% | +5.1% |
| Nov 2025 | NT$145.3 million | +33.6% | +33.5% |
| Oct 2025 | NT$108.8 million | +0.7% | -13.4% |
| Sep 2025 | NT$125.7 million | +4.6% | -0.8% |
| Aug 2025 | NT$126.8 million | +17.0% | +10.1% |
| Jul 2025 | NT$115.2 million | +16.5% | -26.1% |
| Jun 2025 | NT$155.8 million | +37.0% | +32.8% |
| May 2025 | NT$117.3 million | +5.2% | +11.1% |
| Apr 2025 | NT$105.6 million | +14.7% | -0.3% |
| Mar 2025 | NT$105.9 million | +7.2% | -35.2% |
| Feb 2025 | NT$163.3 million | +102.9% | +31.0% |
| Jan 2025 | NT$124.6 million | -6.0% | +0.3% |
| Dec 2024 | NT$124.3 million | +19.5% | +14.3% |
| Nov 2024 | NT$108.7 million | +20.7% | +0.6% |
| Oct 2024 | NT$108.1 million | +23.2% | -10.1% |
Jan–Oct 2026 cumulative: NT$1.42 billion (+13.5% YoY)
Other Biotech & Medical companies
Compare with peers: Arich Enterprise vs PEC / Arich Enterprise vs Lotus Pharm / Arich Enterprise vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
主係流感疫情升溫致相關業績提升。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16